Press Releases Year All20242023202220212020201920182017201620152014 Coherus Announces Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting Apr 24, 2024 Coherus Presents Preclinical Data for CHS-1000, a Novel Anti-ILT4 Antibody, at the 2024 AACR Annual Meeting Apr 08, 2024 Coherus BioSciences Reports Fourth Quarter, Full Year 2023 Financial Results and Provides Current Business Update Mar 13, 2024 Coherus to Report Fourth Quarter and Full Year 2023 Financial Results on March 13, 2024 Mar 05, 2024 Coherus Completes Divestiture of Ophthalmology Franchise Mar 04, 2024 Coherus BioSciences Announces New Employment Inducement Grants Feb 23, 2024 Coherus Announces U.S. Launch of UDENYCA ONBODY™ a Novel and Proprietary State-of-the-Art Delivery System for pegfilgrastim-cbqv Feb 21, 2024 Coherus Amends Term Loan Agreement with Pharmakon Advisors, LP Feb 05, 2024 Coherus Announces Agreement to Divest Ophthalmology Franchise to Sandoz in $170 Million Upfront All Cash Deal Jan 22, 2024 Coherus Presents Positive Phase 2 Clinical Data on Casdozokitug, a First-in-Class IL-27-Targeted Antibody, at the 2024 ASCO GI Cancers Symposium Jan 18, 2024
Year All20242023202220212020201920182017201620152014 Coherus Announces Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting Apr 24, 2024 Coherus Presents Preclinical Data for CHS-1000, a Novel Anti-ILT4 Antibody, at the 2024 AACR Annual Meeting Apr 08, 2024 Coherus BioSciences Reports Fourth Quarter, Full Year 2023 Financial Results and Provides Current Business Update Mar 13, 2024 Coherus to Report Fourth Quarter and Full Year 2023 Financial Results on March 13, 2024 Mar 05, 2024 Coherus Completes Divestiture of Ophthalmology Franchise Mar 04, 2024 Coherus BioSciences Announces New Employment Inducement Grants Feb 23, 2024 Coherus Announces U.S. Launch of UDENYCA ONBODY™ a Novel and Proprietary State-of-the-Art Delivery System for pegfilgrastim-cbqv Feb 21, 2024 Coherus Amends Term Loan Agreement with Pharmakon Advisors, LP Feb 05, 2024 Coherus Announces Agreement to Divest Ophthalmology Franchise to Sandoz in $170 Million Upfront All Cash Deal Jan 22, 2024 Coherus Presents Positive Phase 2 Clinical Data on Casdozokitug, a First-in-Class IL-27-Targeted Antibody, at the 2024 ASCO GI Cancers Symposium Jan 18, 2024
Coherus Announces Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting Apr 24, 2024
Coherus Presents Preclinical Data for CHS-1000, a Novel Anti-ILT4 Antibody, at the 2024 AACR Annual Meeting Apr 08, 2024
Coherus BioSciences Reports Fourth Quarter, Full Year 2023 Financial Results and Provides Current Business Update Mar 13, 2024
Coherus Announces U.S. Launch of UDENYCA ONBODY™ a Novel and Proprietary State-of-the-Art Delivery System for pegfilgrastim-cbqv Feb 21, 2024
Coherus Announces Agreement to Divest Ophthalmology Franchise to Sandoz in $170 Million Upfront All Cash Deal Jan 22, 2024
Coherus Presents Positive Phase 2 Clinical Data on Casdozokitug, a First-in-Class IL-27-Targeted Antibody, at the 2024 ASCO GI Cancers Symposium Jan 18, 2024